Damon Runyon News

May 10, 2024

A tissue biopsy, in which a section of skin is surgically removed for microscopic evaluation, has long been the most effective means of diagnosing skin cancer. But biopsies are invasive and time-consuming procedures, with patients often waiting days for results, developing scars, or forgoing biopsy altogether and opting to “wait and see.” Given that one in five Americans will develop skin cancer in their lifetime, this is a dilemma many of us have experienced firsthand.

May 9, 2024

Immunotherapies to treat pancreatic cancer—a disease with a nearly 90 percent mortality rate—have been the subject of intensive research efforts in recent years, largely because they have succeeded where other treatment approaches have failed. New developments in mRNA vaccines, immune-enhancing therapies, and combination immunotherapy-chemotherapy regimens have marked a new era in pancreatic cancer treatment. But still, for many patients, nothing seems to work.

April 25, 2024

Damon Runyon has announced its 2024 Quantitative Biology Fellows, four exceptional early-career scientists who are bringing cutting-edge computational tools to bear on some of the most important questions in cancer biology. From the packaging of DNA to mechanisms of chemotherapy resistance, their projects aim to shed light on these fundamental questions through large-scale data collection, mathematical modeling, and quantitative analysis.

April 3, 2024

Just as the study of a growing plant or animal must take into account its environment, cancer researchers must look beyond a tumor to understand how the surrounding tissue impacts its development. In the case of gliomas, the most common and aggressive type of brain tumor, this means looking at neurons—what signals they emit, and how these signals may play a role in brain tumor progression.  

March 14, 2024

The Damon Runyon Cancer Research Foundation has named 14 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators. The prestigious, four-year Fellowship encourages the nation's most promising young scientists to pursue careers in cancer research by providing them with independent funding ($300,000 total) to investigate cancer causes, mechanisms, therapies, and prevention.

March 14, 2024

Damon Runyon scientists and industry partners gathered on Thursday, March 7, for the 2024 Accelerating Cancer Cures Symposium, hosted by AbbVie on their campus in South San Francisco.

February 23, 2024

Renal cell carcinoma ranks among the top ten most common cancers globally, with the clear cell subtype (ccRCC) accounting for the majority of metastatic cases. While some ccRCC tumors respond to immunotherapy treatment, it is often difficult to predict which patients will benefit.

February 15, 2024

The Damon Runyon Cancer Research Foundation has announced eight recipients of the 2024 Damon Runyon-Rachleff Innovation Award, established to support “high-risk, high-reward” ideas with the potential to significantly impact the prevention, diagnosis, or treatment of cancer. Five extraordinary early-career researchers will receive initial grants of $400,000 over two years, and each will have the opportunity to receive two additional years of funding (for a potential total of $800,000).

February 12, 2024

On Saturday, February 10, 2024, an intrepid team of twenty scientific luminaries led by biotech journalist and mountaineer Luke Timmerman embarked upon the trip of a lifetime—a hike to the summit of Mt. Kilimanjaro, the African continent’s highest peak. In advance of the expedition, the team trained for hiking at more than 19,000 feet above sea level, enlisted the support of friends and colleagues, and together raised more than $1 million to support Damon Runyon’s brave and bold cancer researchers.

February 1, 2024

The Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital today announce the inaugural class of pediatric cancer research fellows. Each of the five fellows will receive funding for four years ($300,000 total) to support an innovative project in basic or translational research with the potential to significantly impact the diagnosis or treatment of one or more pediatric cancers.